Catheter reprices options for CEO David A. Jenkins and CFO Philip Anderson
Catheter repriced stock options for CEO David A. Jenkins and CFO Philip Anderson to $0.152 per share, adjusting to $1.52 due to a 1-for-10 reverse split. The changes, approved by stockholders, take effect on Sept 30, 2026, and Oct 5, 2026, respectively. Jenkins holds options for 89,999 shares, and Anderson for 66,315 shares, according to the company.
How this was made
The 30-second read
Why it matters
The repricing lowers the exercise price of existing options, which could be viewed positively by investors as it reduces potential dilution and aligns executive incentives with the post‑split share price.
Market read
A corporate action affecting executive compensation; limited immediate market impact but worth noting for option holders and shareholders.
What to watch
Potential tax implications for executives and the effect on future compensation planning.
Background
The filing is an 8‑K disclosure from Catheter Precision, Inc. announcing a one‑time stock option repricing approved by shareholders.
Ticker impact
Catheter Precision repriced outstanding stock options for its CEO and CFO to $0.152 per share, effective after a 1‑for‑10 reverse split on Oct 5 2026.
likely modest upward pressure as the market prices in a lower option strike and reduced dilution risk
The adjustment is a corporate action that changes the economics of existing option grants; such moves typically have a small but positive effect on the stock.
Market effects
minimal impact on the broader medical device sector
none
none
Counterpoint
The repricing may signal management concerns about over‑valuation of prior grants, suggesting deeper issues.
Key entities
- companyCatheter Precision, Inc.
Medical device company filing the 8‑K.
- executiveDavid A. Jenkins
Executive Chairman and CEO of Catheter Precision.
- executivePhilip Anderson
Chief Financial Officer of Catheter Precision.